The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Cancer
Egile Nagusiak: Ross, Jeffrey S., Wang, Kai, Chmielecki, Juliann, Gay, Laurie, Johnson, Adrienne, Chudnovsky, Jacob, Yelensky, Roman, Lipson, Doron, Ali, Siraj M, Elvin, Julia A., Vergilio, Jo‐Anne, Roels, Steven, Miller, Vincent A, Nakamura, Brooke N., Gray, Adam, Wong, Michael K, Stephens, Philip J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2016
Gaiak:
Cancer Genetics and Epigenetics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5049644/
https://ncbi.nlm.nih.gov/pubmed/26314551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29825
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak